Opendata, web and dolomites

MPIPETrace SIGNED

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MPIPETrace project word cloud

Explore the words cloud of the MPIPETrace project. It provides you a very rough idea of what is the project "MPIPETrace" about.

positron    absolute    risk    spect    advantages    serve    trials    cardiovascular    shorter    synthesis    nuclear    11c    unnecessary    projected    tests    compelling    probes    shortage    imaging    pay    commercialize    prognostic    artery    western    dmdpa    trend    mpi    business    disease    abundance    players    cardiac    opportunity    doses    rates    death    emission    measuring    offers    myocardial    toxicity    superior    cad    adverse    biomarker    pet    adoption    feasibility    deals    downstream    publications    scanners    predict    image    invasive    globally    2020    marker    outnumber    market    form    patients    partnering    reserve    possibility    consultancy    motivated    evaluation    negotiations    indicate    volume    heart    perfusion    world    economic    blood    retention    attack    events    discovery    confirmed    quality    clinical    agents    risks    efficient    flow    period    coronary    willingness    tomography    diagnostic    quantifying    radiation    stakeholders   

Project "MPIPETrace" data sheet

The following table provides information about the project.

Coordinator
SYNEKTIK SPOLKA AKCYJNA 

Organization address
address: AL. WITOSA 31
city: WARSZAWA
postcode: 00-710
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Poland [PL]
 Project website http://www.synektik.com.pl/
 Total cost 3˙687˙250 €
 EC max contribution 3˙687˙250 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNEKTIK SPOLKA AKCYJNA PL (WARSZAWA) coordinator 3˙687˙250.00

Map

 Project objective

Coronary Artery Disease (CAD) is the most common form of heart disease and is the leading cause of death in Europe and the Western World. Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) offers the unique possibility of measuring and quantifying myocardial blood flow and coronary flow reserve in absolute terms, which serve as a prognostic marker for adverse cardiac events: It can predict the risk of heart attack. PET also offers advantages such as: superior image quality and diagnostic ability, reduction of unnecessary invasive downstream procedures and reduction of patients’ risks due to reduced radiation doses and shorter period of radiation retention. Currently, there is a shortage of available, simple and efficient PET myocardial perfusion imaging agents. Motivated by the growing business opportunity in PET cardiac imaging and the success of completed synthesis and evaluation discovery process, as well as pre-clinical trials and toxicity tests, the objective of this project is Phase 1 and 2 clinical trials of the novel biomarker [11C]-DMDPA for Myocardial Perfusion Imaging using Positron Emission Tomography, and to commercialize it globally. The adoption of Positron Emission Tomography for Myocardial Perfusion Imaging will occur as a result of numerous advantages and the growing abundance and availability of PET scanners in recent and future years. There is compelling evidence that our novel biomarker is addressing a high growth trend in a high volume market of the cardiovascular disease nuclear imaging, and specifically the growing need of non-invasive PET cardiac probes. According to publications, the projected growth rates indicate that PET will outnumber SPECT cardiac procedures by 2020. The willingness to pay has been confirmed during our economic feasibility assessment of the project, by means of consultancy with key stakeholders and negotiations with a number of key players on Diagnostic Partnering deals.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MPIPETRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MPIPETRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)

FETAL MONITORING (2016)

Safe and accurate fetal monitoring

Read More  

PReDicT (2015)

Predicting Response to Depression Treatment

Read More  

MPIPETrace (2015)

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.

Read More